Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumors × tomivosertib × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

Paclitaxel 14 Gemcitabine 11 atezolizumab 9 Carboplatin 9 pembrolizumab 8 Docetaxel 8 Irinotecan 7 Bevacizumab 7 Cetuximab 6 Sunitinib 5 Leucovorin 5 Injections 5 Fluorouracil 5 Cyclophosphamide 5 Capecitabine 5 olaparib 4 navitoclax 4 liposomal doxorubicin 4 Topotecan 4 Oxaliplatin 4 Nivolumab 4 Erlotinib Hydrochloride 4 temsirolimus 3 spartalizumab 3 pazopanib 3 lenvatinib 3 fludarabine 3 Cisplatin 3 zolbetuximab 2 tocilizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03616834 2023-03-22

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Effector Therapeutics

Phase 2 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡